Nath Bio-Genes (India) Limited has informed the Exchange about General Updates
NATHBIOGEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nath Bio-Genes reported FY26 revenue of INR 4,316 million (19% YoY growth) with PAT of INR 384 million (9% margin), though PAT margin declined due to normalized tax rate of 11% vs 5% in FY25. Gross margin normalized to 56% from elevated 63% in FY25. Key crops performed well: cotton volume grew 22% YoY, paddy volume rose 25% YoY with 37% value growth, and maize surged 54% in volume and 78% in value to contribute 10.7% of revenue. Uzbekistan joint venture contributed INR 15 crores for the first time. The company guided for 15-20% top line growth in FY27 with maintained or slightly improving EBITDA margins. Management stated they are conservative in targets, prefer under-committing and over-performing.
Strong revenue growth was offset by margin normalization; the stock may face pressure from the lower PAT margin and negative cash flow due to inventory build-up. However, the robust product pipeline, international expansion, and management's confidence in FY27 guidance suggest potential for continued growth.